RxDoctor Payments Data

Stephen Esposito, MD

Gastroenterology · Flushing, NYNPI 1639165293

Payments from drug & device makers

$190,143in general payments, 2019–2025

Across 1,000 payments — averaging $190.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$101K
  • Gilead$44K
  • Madrigal Pharmaceuticals$33K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Olympus America Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $7K from 38 others

What the payments were for

  • Consulting fees$7,8304%
  • Speaking & faculty fees$137,48172%
  • Travel & lodging$22,12512%
  • Food & beverage$20,52811%
  • Education$1230%
  • Other$2,0571%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,143 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$107,899
Medicare patients
243
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom95$392,611
LinzessLinaclotide177$137,828
XifaxanRifaximin35$126,290
CreonLipase/Protease/Amylase37$112,063
IbsrelaTenapanor Hcl34$69,645
TrulancePlecanatide76$55,742
ZenpepLipase/Protease/Amylase20$49,188
OzempicSemaglutide43$41,276
VoqueznaVonoprazan Fumarate60$40,225
VemlidyTenofovir Alafenamide28$39,710
MotegrityPrucalopride Succinate40$35,067
Ursodiol51$28,028
Entecavir53$13,216
Dexlansoprazole DrDexlansoprazole47$13,039
Mesalamine18$11,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$32,945$392,61195 claims
AbbVieLinzess, Creon$100,562$249,891214 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$2,791$183,652123 claims
Ardelyx, Inc.Ibsrela$396$69,64534 claims
Aimmune Therapeutics, Inc.Zenpep$14$49,18820 claims
Novo NordiskOzempic$21$41,27643 claims
Phathom Pharmaceuticals, Inc.Voquezna$367$40,22560 claims
GileadVemlidy$44,116$39,71028 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,163$35,06740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →